Arjona Ferreira Juan Camilo 4

What Happened
Juan Camilo Arjona Ferreira, Organon & Co.'s Head of R&D and Chief Medical Officer, received a grant of 200,333 restricted stock units (RSUs) on March 31, 2026. At the same time, 13,431 previously granted RSUs vested and were converted into shares. To cover tax withholding on the vested shares, 4,820 shares were surrendered at an effective price of $5.70 per share, generating $27,474 in withheld taxes.

Key Details

• Transaction date: March 31, 2026; Form 4 filed April 2, 2026. No late-filing indication in the provided report.
• New grant: 200,333 RSUs (each RSU = right to 1 share). These RSUs vest in three equal installments: Mar 31, 2027; Mar 31, 2028; Mar 31, 2029. (Footnotes F2, F3)
• Vested conversion: 13,431 RSUs converted to shares (exercise/conversion code M).
• Tax withholding: 4,820 shares withheld/disposed to satisfy tax liability at $5.70/share = $27,474 (code F). Price per share reflects Organon's closing market price on March 30, 2026 (Footnote F1).
• Prior grant context: 40,295 RSUs granted on Mar 31, 2025; one-third of that grant vested on Mar 31, 2026 (Footnote F4).
• Amount owned following the transactions is not specified in the provided excerpt.

Context
This filing reflects typical equity compensation activity: new RSU awards and the vesting/conversion of previously granted RSUs with shares withheld for taxes. These are not open-market purchases or sales of shares by the insider and therefore do not necessarily signal a trading view — they document compensation and standard tax withholding.